A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases.
about
Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Multimodality therapy: bone-targeted radioisotope therapy of prostate cancerBone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts.Predictors of androgen independence in metastatic prostate cancer.
P2860
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A Phase I/II study of strontiu ...... carcinoma and bone metastases.
@ast
A Phase I/II study of strontiu ...... carcinoma and bone metastases.
@en
type
label
A Phase I/II study of strontiu ...... carcinoma and bone metastases.
@ast
A Phase I/II study of strontiu ...... carcinoma and bone metastases.
@en
prefLabel
A Phase I/II study of strontiu ...... carcinoma and bone metastases.
@ast
A Phase I/II study of strontiu ...... carcinoma and bone metastases.
@en
P2093
P356
P1433
P1476
A Phase I/II study of strontiu ...... carcinoma and bone metastases.
@en
P2093
Christopher J Logothetis
Dallas Williams
Ebrahim S Delpassand
Lance C Pagliaro
Randall E Millikan
Shi-Ming Tu
P304
P356
10.1002/CNCR.11412
P407
P577
2003-06-01T00:00:00Z